Welcome to our dedicated page for Valneva Se SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.Valneva reported consolidated revenues of €97.6 million for the six months ended June 30, 2025, with product sales rising to €91.0 million from €68.3 million a year earlier. Improved manufacturing performance lifted the product gross margin (excluding IXCHIQ) to 59.2%, supporting stronger cash generation despite a reported net loss of €20.8 million and an Adjusted EBITDA loss of €6.0 million. Cash and cash equivalents were €161.3 million.
Operationally, Valneva continued commercial rollouts and partnerships: IXCHIQ received marketing authorizations (including Brazil and the UK), a $32.8 million DoD supply contract for IXIARO was secured, an exclusive German distribution deal with CSL Seqirus was signed, and the VALOR Phase 3 Lyme trial completed full vaccination with Pfizer aiming for regulatory filings in 2026 subject to positive data. The company is advancing Shigella and Zika programs and expects to focus sales on proprietary vaccines while winding down third-party distribution.
Valneva SE filed a Form 6-K report on June 28, 2025, indicating the issuance of a press release dated June 26, 2025. The filing was signed by CEO and President Thomas Lingelbach.
This Form 6-K submission serves primarily as a notification of foreign issuer disclosure, with the company confirming it files annual reports under Form 20-F. The press release content (Exhibit 99.1) is referenced but not detailed in the main filing.
Notably, the information contained in this Form 6-K, including Exhibit 99.1, has been incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-286071), which could indicate potential future securities offerings or other significant corporate actions.
Valneva SE (VALN) filed a routine Form 6-K with the U.S. SEC on 25 June 2025. The submission simply furnishes a company press release dated the same day as Exhibit 99.1 and explicitly incorporates that release into Valneva’s effective shelf Registration Statement on Form F-3 (File No. 333-286071). No financial statements, earnings figures, or transactional details accompany the filing. The document, signed by CEO and President Thomas Lingelbach, serves an administrative purpose—ensuring U.S. investors have access to the referenced press release within Valneva’s formal disclosure record.
FAQ
What is the current stock price of Valneva Se (VALN)?
What is the market cap of Valneva Se (VALN)?
